Biomarkers of pulmonary fibrosis in COVID-19 and postcovid syndrome
COVID-19 can occur in the form of an acute respiratory viral infection of a mild course, or in a severe form. Both effective treatments for the acute phase of the disease and the clinical and functional long-term consequences of COVID-19, which include the complexity of symptoms and organ damage ref...
Saved in:
| Main Authors: | M. K. Kurbanaliev, T. A. Potselueva, E. A. Lyakh, D. A. Shtonda, I. V. Rodionova, V. V. Skvortsov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Open Systems Publication
2022-10-01
|
| Series: | Лечащий Врач |
| Subjects: | |
| Online Access: | https://journal.lvrach.ru/jour/article/view/966 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TFR1 as a Biomarker of Pulmonary Fibrosis Development in COPD Patients
by: Wu Y, et al.
Published: (2025-08-01) -
Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021-12-01) -
Trends and hotspots in pulmonary fibrosis biomarker research: a bibliometric analysis
by: Ling Wang, et al.
Published: (2025-04-01) -
ACTUAL PRINCIPLES OF THERAPY CHRONIC HEPATITIS OF VARIOUS ETIOLOGIES
by: I. V. Semenova, et al.
Published: (2015-12-01) -
Biomarkers of renal transplant fibrosis
by: O. R. Bystrova, et al.
Published: (2022-09-01)